Liquidia Technologies is applying its novel PRINT® technology toward internal, licensed, and co-development opportunities, including:

  • Internal development of our lead product candidate, LIQ861, for pulmonary arterial hypertension (PAH). After consultation with the FDA, we advanced LIQ861 from a Phase 1 trial directly to our open-label Phase 3 trial (INSPIRE).
  • Internal development of LIQ865, which is currently being evaluated in a Phase 1 trial for post-operative pain.
  • Partnerships with leading pharmaceutical companies such as GlaxoSmithKline and others undisclosed.

1. COPD is chronic obstructive pulmonary disease.

© 2018 Liquidia Technologies